DelSiTech: Clinical-Stage Drug Delivery Company Raises €10 Million

By Dan Anderson • Jan 17, 2024

Clinical-stage drug delivery and development company DelSiTech recently announced the successful completion of a €10 million financing round, the largest single financing round in the company’s history. The funding was co-led by new investors DRW Venture Capital LLC, headquartered in Chicago, IL, USA, and Tolmar International Ltd, based in Dublin, Ireland, which together contributed more than EUR 9 million. The remaining financing was funded by existing DelSiTech shareholders.

The proceeds from the funding will be used to further build the company and advance its unique, in-house, silica-based, drug delivery technology platform into clinical development, and expanding its in-house manufacturing capability to support the development programs of multiple partners.

KEY QUOTES:

“We welcome DRW and Tolmar to DelSiTech as new investors and strategic partners at an important time of growth and development. This financing marks a significant milestone on our journey as one of the world’s leading drug delivery technology providers, with an attractive internal pipeline of controlled release drug products based on Silica Matrix. This investment, together with our increasing revenues from our own drug development, will help us to reach our strategic business goals and objectives over the next couple of years, as we continue to address high unmet clinical and commercial needs for the benefit of patients.” 

— Lasse Leino, Chief Executive Officer at DelSiTech

“We have seen the tremendous importance of strengthening our world’s capabilities to bring new treatments online to address viruses and diseases. We have been impressed by the work DelSiTech is doing in this area and by the innovative technologies its team has developed, and we are pleased to join this round to help them accelerate this work.”

— David Nelson, Partner at DRW

“This investment further advances Tolmar’s overall business strategy to develop therapies for the benefit of patients around the globe. In addition, we are confident that this investment will lead to profitable growth by further leveraging DelSiTech’s differentiated technology platform.”

— Anil D’Souza, President and Chief Executive Officer of Tolmar